Identification of protamine 1 as a novel cancer-testis antigen in early chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 144, Issue 5, 2009, Pages 660-666

  Meklat, Farouk ^b   Zhang, Yana ^b   Shahriar, Masum ^b   Ahmed, Sharif U ^b   Li, Wei ^b   Voukkalis, Nikolaos ^c   Wang, Zhiqing ^b   Zhang, Jian ^b   Mastulov, Suhkrob ^b   Jewell, Andrew ^d   Giannakouros, Thomas ^c   Lim, Seah H ^a,b  

^a TEXAS ONCOLOGY   (United States)

^b Harrington Regional Medical Center Inc   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer testis antigen; Chronic lymphocytic leukaemia; Protamine 1; Zap 70

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER VACCINE; IMMUNOGLOBULIN G; PROTAMINE; PROTAMINE P1; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; CANCER IMMUNOLOGY; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIBODIES; B-LYMPHOCYTES; CANCER VACCINES; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE LIBRARY; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PROTAMINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEMINAL VESICLE SECRETORY PROTEINS; TESTIS; TUMOR MARKERS, BIOLOGICAL; TWO-HYBRID SYSTEM TECHNIQUES; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 58849156900     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07502.x     Document Type: Article

References (19)

1. Asimakopoulos, F.A., White, N.J., Nacheva, E. Green, A.R. (1994) Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood, 84, 3086 3094.
2. De Lamirande, E., Yoshida, K., Yoshiike, T.M., Iwamoto, T. Gagnon, C. (2001) Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process. Journal of Andrology, 22, 672 679.
3. Foa, R., Fierro, M.T., Lusso, P., Raspadori, D., Ferrando, M.L., Matera, L., Malavasi, F. Lauria, F. (1986) Reduced natural killer T-cells in B-cell chronic lymphocytic leukemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28. British Journal of Haematology, 62, 151 154.
4. Gitelson, E., Hammond, C., Mena, J., Lorenzo, M., Buckstein, R., Berinstein, N.L., Imrie, K. Spaner, D.E. (2003) Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clinical Cancer Research, 9, 1656 1665.
5. Goddard, R.V., Prentice, A.G., Copplestone, J.A. Kaminski, E.R. (2001) Generation in vitro of B-cell chronic lymphocytic leukemia-prolfierative and specific HLA-class II-restricted cytotoxic T-cell response using autologous dendritic cells pulsed with tumour cell lysate. Clinical and Experimental Immunology, 126, 16 28.
6. Li, Z., Li, W., Meklat, F., Wang, Z., Zhang, J., Zhang, Y. Lim, S.H. (2007) A yeast two-hybrid system using Sp17 identified Ropporin as a novel cancer-testis antigen in hematologic malignancies. International Journal of Cancer, 121, 1507 1511.
7. Nikolakaki, E., Drosou, V., Sanidas, I., Peidis, P., Papamarcaki, T., Iakoucheva, L.M. Giannakouros, T. (2008) RNA association or phosphorylation of the RS domain prevents aggregation of RS domain-containing proteins. Biochimica et Biophysica Acta, 1780, 214 225.
8. Norris, D.A., Weston, W.L., Tubergen, D.G., Rose, B. Odom, L.F. (1980) Monocyte chemotaxis in leukemia patients. Journal of Laboratory and Clinical Medicine, 95, 609 615.
9. Oliva, R. (2006) Protamines and male infertility. Human Reproduction Update, 2, 417 435.
10. Oliva, R. Dixon, G.H. (1991) Vertebrate protamine genes and the histone-to-protamine replacement reaction. Progress in Nucleic Acid Research and Molecular Biology, 40, 25 94.
11. Orsini, E., Guarini, A., Chiaretti, S., Mauro, F.R. Foa, R. (2003) The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Research, 63, 4497 4506.
12. Ravandi, F. O'Brien, S. (2006) Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy, 55, 197 209.
13. Ribera, J.M., Vinolas, N., Urbaon-Ispizua, A., Gallart, T., Montserrat, E. Rozman, C. (1987) "Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. Blood Cells, 12, 471 483.
14. Ritgen, M., Stilgenbauer, S., von Neuhoff, N., Humpe, A., Bruggemann, M., Pott, C., Raff, T., Krober, A., Bunjes, D., Schlenk, R., Schmitz, N., Dohner, H., Kneba, M. Dreger, P. (2004) Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measured with quantitative PCR. Blood, 104, 2600 2602.
15. Ulvsback, M., Lazure, C., Lilja, H., Spurr, N.K., Rao, V.V., Loffler, C., Hansmann, I. Lundwall, A. (1992) Gene structure of semenogelin I and II. The predominant proteins in human semen are encoded by two homologous genes on chromosome 20. Journal of Biological Chemistry, 267, 18080 18084.
16. Wang, Z., Zhang, Y., Ramsahoye, B., Bowen, D. Lim, S.H. (2004) Sp17 gene expression in tumor cells is regulated by promoter methylation. British Journal of Cancer, 91, 1597 1603.
17. Wang, Z., Zhang, J., Zhang, Y. Lim, S.H. (2006) SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically. International Journal of Cancer, 118, 1436 1444.
18. Zhang, Y., Wang, Z., Liu, H., Giles, F.J. Lim, S.H. (2003) Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies. Journal of Immunotherapy, 26, 461 467.
19. Ziegler-Heitbrock, H.W., Schlag, R., Flieger, D. Thiel, E. (1989) Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood, 73, 426 1430.